US Patent Issued to University of Cincinnati on Nov. 25 for "Enhanced efficacy of combination of gemcitabine and phosphatidylserine-targeted nanovesicles against pancreatic cancer" (Ohio Inventors)

ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,478,658, issued on Nov. 25, was assigned to University of Cincinnati (Cincinnati).

"Enhanced efficacy of combination of gemcitabine and phosphatidylserine-targeted nanovesicles against pancreatic cancer" was invented by Xiaoyang Qi (Cincinnati) and Kombo Flore N'guessan (Cincinnati).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure concerns methods for treating pancreatic cancer cells with a combination of gemcitabine (GEM) and SapC-DOPS. In some aspects, GEM treatment preferentially targets G1 phase cells which are low in surface phosphatidylserine (PS), resulting in an increased median surface PS level of PDAC cells. Inversely, SapC...